Contango ORE (CTGO) nominates two directors to Board

Contango ORE, Inc. (NYSE: CTGO) is pleased to announce that it has nominated two new independent directors to its board of directors (the "Board"), and that it will hold its 2025 Annual Meeting of Stockholders (the "Annual Meeting") virtually on Tuesday, June 10, 2025 at 10:00 am Central Time. The notice of the Annual Meeting and proxy materials will be sent on or shortly after April 29, 2025 to stockholders of record as of the close of business on April 11, 2025.

The Board, based on the recommendation of its Nominating and Corporate Governance Committee, has nominated Messrs. Michael Cinnamond and Clynton Nauman to stand for election to the Board. Messrs. Joe Compofelice and Curtis Freeman are not standing for re-election, and their current terms as directors will end at the Annual Meeting. Mr. Compofelice has been a director of the Company since 2010, while Mr. Freeman has been a director since 2022. Their decision not to stand for re-election is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The remaining current directors will stand for re-election at the Annual Meeting.

Brad Juneau, Contango's Chairman, said "On behalf of all shareholders and Board members, we would like to thank Joe and Curt for their dedication to advancing the Manh Choh project from an early-stage exploration concept to a producing mine. Their guidance and hard work over the years have resulted in building true shareholder value. On behalf of us all – Thank you!"

Rick Van Nieuwenhuyse, the Company's President and CEO added, "We are very pleased to nominate both Mike and Clynt to the Board. Mike currently serves as Senior Vice President of Finance and Chief Financial Officer of B2Gold Corp., a company with a market capitalization of over $4 billion, bringing a strong finance and capital markets background to the Board, while Clynt brings a wealth of knowledge as a seasoned mining executive with over 45 years of experience building and operating mines internationally, including numerous projects in Alaska and Yukon."

Pursuant to Rule 14a-5(f) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), because the Company did not hold a 2024 Annual Meeting of Stockholders, the Company is hereby providing notice of the deadlines for submission of stockholder proposals and nominations of individuals for election to the Board.

Stockholders of the Company who wish to have a proposal considered for inclusion in the Company's proxy materials for the Annual Meeting pursuant to Rule 14a-8 of the Exchange Act must ensure that proper written notice thereof is delivered to: Corporate Secretary, Contango ORE, Inc., 516, 2^nd Avenue, Suite 401, Fairbanks, Alaska 99701, no later than the close of business on April 28, 2025, which the Company has determined to be a reasonable time before it begins to print and send its proxy materials for the Annual Meeting. Any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission (the "SEC") and the Company's bylaws (as amended, the "Bylaws") in order to be eligible for inclusion in the proxy materials for the Annual Meeting.

In addition, in accordance with the requirements contained in the Company's Bylaws, stockholders of the Company who wish to bring business before the Annual Meeting or nominate a person for election as a director, outside of Rule 14a-8 of the Exchange Act, must ensure that proper written notice of such proposal (including all information specified in the Company's Bylaws) is received by the Company's Corporate Secretary at the address specified above no later than the close of business on April 28, 2025. Any such proposal or nomination must also meet the requirements set forth in the rules and regulations of the SEC and the Company's Bylaws.

You May Also Be Interested In

• Kadima sues NRx Pharmaceuticals over failed acquisition deal
• Canaan CEO and CFO buy 1.07M ADS shares at $0.35 each
• MapLight Therapeutics adds two directors to its board